ACRS — Aclaris Therapeutics, Inc. catalysts
Next verified catalyst
2026-08-01 — ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-08 (month) in 1mo
ESTIMATED |
READOUT
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Phase 2 · Atopic Dermatitis, Atopic |
ACRS Aclaris Therapeutics, Inc. | ATI-045 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|